Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 4/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216526 | 0.86 | TBXA2R (0.42) | TBXA2RHTR1AHTR1DHTR2CALDH1A1 | |
| SCHEMBL6213248 | 0.86 | HPGD (0.40) | TBXA2RHTR1AHTR1DHTR2CALDH1A1 | |
| SCHEMBL6215027 | 0.84 | CHRM4 (0.41) | TBXA2R | |
| SCHEMBL2639560 | 0.84 | HTR1A (0.45) | TBXA2RMT-CO2LMNAHTR1AHTR1D | |
| SCHEMBL6242842 | 0.83 | HTR1A (0.40) | TBXA2RLMNAHTR1AHTR1DHTR2C | |
| SCHEMBL6214922 | 0.82 | HTR1A (0.38) | TBXA2RLMNAHTR1AHTR1DHTR2C | |
| SCHEMBL6216667 | 0.82 | TBXA2R (0.34) | TBXA2RHTR1AHTR1DHTR2CTBXAS1 | |
| SCHEMBL6212619 | 0.81 | CHRM4 (0.46) | — | |
| SCHEMBL6216818 | 0.81 | NPC1 (0.41) | HTR1AHTR1DHTR2CALDH1A1KDM4E | |
| SCHEMBL6211980 | 0.80 | RAB9A (0.38) | TBXA2RHTR1AHTR1DHTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222182-B1 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMA INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1222182-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | Aventis Pharmaceuticals Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | TBXA2R 28/4885MT-CO2 2468/4885LMNA 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.